ABL is a contract research and contract manufacturing organization with over 50 years of experience partnering with clients to meet their preclinical product development goals.
We ensure clients that their protein therapeutics, vaccines, viral vectors and other therapeutics get into the clinic efficiently and effectively.
Our CMO group has been producing cGMP material since 1985 and continues to grow. We relocated to a new larger facility in 2011 which houses our cGMP production and fill suites along with process development and cell line development labs. Our multi-use production facility has been designed with three separate production suites; a mammalian expression, a microbial expression, and a viral vector suite. At our new facility we have been sure to stress and implement single-use manufacturing technology which translates to shorter lead times and lower costs for client products. Our history, capabilities, and expertise allow ABL to partner with clients and help remove the risk associated with product development. ABL is a unique contract service provider in that we can truly help our clients not only identify and screen for their lead compounds, but also produce the necessary clinical material. Our scientists focus on designing processes to ensure we do all that we can to remove many of the pitfalls that can be encountered on the way to the clinic. ABL strives to become a seamless extension of our clients’ product development group.